GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2133–2161 https://doi.org/10.1016/S0140-6736(24)00757-8 (2024).
GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 403, 2204–2256 https://doi.org/10.1016/S0140-6736(24)00685-8 (2024).
Anderson, D. J. & Locke, J. E. Progress towards solving the donor organ shortage. Nat. Rev. Nephrol. 19, 83–84 https://doi.org/10.1038/s41581-022-00664-y (2023).
Sykes, M. Developing pig-to-human organ transplants. Science 378, 135–136 https://doi.org/10.1126/science.abo7935 (2022).
Yamada, K., Griesemer, A. & Okumi, M. Pigs as xenogeneic donors. Transplant. Rev. 19, 164–177 https://doi.org/10.1016/j.trre.2005.10.004 (2005).
Sykes, M. & Sachs, D. H. Progress in xenotransplantation: overcoming immune barriers. Nat. Rev. Nephrol. 18, 745–761 https://doi.org/10.1038/s41581-022-00624-6 (2022).
Parker, W., Bruno, D., Holzknecht, Z. E. & Platt, J. L. Characterization and affinity isolation of xenoreactive human natural antibodies. J. Immunol. 153, 3791–3803 https://doi.org/10.4049/jimmunol.153.8.3791 (1994).
Galili, U., Shohet, S. B., Kobrin, E., Stults, C. L. & Macher, B. A. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263, 17755–17762 https://doi.org/10.1016/S0021-9258(19)77900-9 (1988).
Candinas, D. et al. T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection. Transplantation 62, 1920–1927 https://doi.org/10.1097/00007890-199612270-00042 (1996).
Cardona, K. et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat. Med. 12, 304–306 https://doi.org/10.1038/nm1375 (2006).
Shimizu, A. et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from α1,3-galactosyltransferase gene-knockout pigs in baboons. Am. J. Pathol. 172, 1471–1481 https://doi.org/10.2353/ajpath.2008.070672 (2008).
Robson, S. C., Cooper, D. K. & d’Apice, A. J. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 7, 166–176 https://doi.org/10.1034/j.1399-3089.2000.00067.x (2000).
Ryczek, N., Hryhorowicz, M., Zeyland, J., Lipiński, D. & Słomski, R. CRISPR/Cas technology in pig-to-human xenotransplantation research. Int. J. Mol. Sci. 22, 3196 https://doi.org/10.3390/ijms22063196 (2021).
Hryhorowicz, M., Zeyland, J., Słomski, R. & Lipiński, D. Genetically modified pigs as organ donors for xenotransplantation. Mol. Biotechnol. 59, 435–444 https://doi.org/10.1007/s12033-017-0024-9 (2017).
Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR–Cas9 for genome engineering. Cell 157, 1262–1278 https://doi.org/10.1016/j.cell.2014.05.010 (2014).
Längin, M. et al. Consistent success in life-supporting porcine cardiac xenotransplantation. Nature 564, 430–433 https://doi.org/10.1038/s41586-018-0765-z (2018).
Anand, R. P. et al. Design and testing of a humanized porcine donor for xenotransplantation. Nature 622, 393–401 https://doi.org/10.1038/s41586-023-06594-4 (2023).
Montgomery, R. A. et al. Results of two cases of pig-to-human kidney xenotransplantation. N. Engl. J. Med. 386, 1889–1898 https://doi.org/10.1056/NEJMoa2120238 (2022). This study reports the transplantation of genetically modified pig kidneys into two brain-dead human recipients, maintained for 54 h—the kidneys produced urine, demonstrated functional activity and showed no evidence of hyperacute rejection.
Kawai, T. et al. Xenotransplantation of a porcine kidney for end-stage kidney disease. N. Engl. J. Med. 392, 1933–1940 https://doi.org/10.1056/NEJMoa2412747 (2025). This case describes a genetically modified pig kidney transplanted into a living patient with end-stage renal disease, functioning for 52 days—the graft showed no hyperacute rejection and sustained urine production, and a TCMR episode responded to treatment.
Moazami, N. et al. Pig-to-human heart xenotransplantation in two recently deceased human recipients. Nat. Med. 29, 1989–1997 https://doi.org/10.1038/s41591-023-02471-9 (2023). This study presents two cases of heart xenotransplantation in brain-dead human recipients, maintained for 66 hours—the grafts exhibited preserved cardiac function and no signs of hyperacute rejection.
Mohiuddin, M. M. et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet 402, 397–410 https://doi.org/10.1016/S0140-6736(23)00775-4 (2023). This study characterizes the rejection mechanisms leading to graft failure at 60 days, identifying AMR, potential PCMV–PRV reactivation and IVIG-associated immune activation as contributing factors.
Griffith, B. P. et al. Genetically modified porcine-to-human cardiac xenotransplantation. N. Engl. J. Med. 387, 35–44 https://doi.org/10.1056/NEJMoa2201422 (2022). This landmark case report describes the surgical procedure and early clinical course following transplantation of a 10GE pig heart, demonstrating absence of hyperacute rejection and short-term haemodynamic stability in a patient with end-stage heart failure.
Tao, K.-S. et al. Gene-modified pig-to-human liver xenotransplantation. Nature 641, 1029–1036 https://doi.org/10.1038/s41586-025-08799-1 (2025). This study details the transplantation of a pig liver into a brain-dead human recipient, maintained for up to 10 days—the graft demonstrated metabolic function and no evidence of rejection.
Griffith, B. P. et al. Transplantation of a genetically modified porcine heart into a live human. Nat. Med. https://doi.org/10.1038/s41591-024-03429-1 (2025). A pig-to-human heart xenotransplant functioned for 40 days with preserved haemodynamics and no hyperacute rejection—emerging signs of AMR were treated with an innovative immunosuppressive regimen.
Tao, K.-S. et al. Immune cell landscape in a human decedent receiving a pig liver xenograft. Nat. Med. 31, 2611–2621 https://doi.org/10.1038/s41591-025-03860-y (2025).
He, J. et al. Pig-to-human lung xenotransplantation into a brain-dead recipient. Nat. Med. 31, 3388–3393 https://doi.org/10.1038/s41591-025-03861-x (2025).
Healey, N. World-first pig kidney trials mark turning point for xenotransplantation. Nat. Med. 31, 1040–1041 https://doi.org/10.1038/d41591-025-00020-0 (2025).
Montgomery, R. A. et al. Physiology and immunology of a pig-to-human decedent kidney xenotransplant. Nature 650, 218–229 https://doi.org/10.1038/s41586-025-09847-6 (2026). This study reports the transplantation of a genetically modified pig kidney into a brain-dead human recipient, maintained for 61 days—AMR was treated successfully, demonstrating the importance of pre-existing donor-reactive T cell clones in the process.
Loupy, A. et al. Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study. Lancet 402, 1158–1169 https://doi.org/10.1016/S0140-6736(23)01349-1 (2023). This study presents the use of integrated immune profiling to monitor a kidney xenograft, uncovering early signs of AMR and demonstrating the added diagnostic value of high-dimensional immunomonitoring.
Wang, Y. et al. Pig-to-human kidney xenotransplants using genetically modified minipigs. Cell Rep. Med. 5, 101744 https://doi.org/10.1016/j.xcrm.2024.101744 (2024).
Ribas, G. T. et al. Immune profiling in a living human recipient of a gene-edited pig kidney. Nat. Med. 32, 270–280 https://doi.org/10.1038/s41591-025-04053-3 (2026).
Porrett, P. M. et al. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am. J. Transplant. 22, 1037–1053 https://doi.org/10.1111/ajt.16930 (2022).
Jones-Carr, M. E. et al. C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation. J. Clin. Invest. 134, e175996 https://doi.org/10.1172/JCI175996 (2024).
Mohiuddin, M. M., Tully, A., Galindo, J. & Singh, A. K. Comprehensive multimodal phenotyping as a novel method evaluating xenograft rejection. Transplantation 108, 1038–1039 https://doi.org/10.1097/TP.0000000000004965 (2024).
Peterson, L. et al. Physiological basis for xenotransplantation from genetically modified pigs to humans. Physiol. Rev. 104, 1409–1459 https://doi.org/10.1152/physrev.00041.2023 (2024).
McMorrow, I. M., Comrack, C. A., Sachs, D. H. & DerSimonian, H. Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(α1,3)galactose epitope. Transplantation 64, 501–510 https://doi.org/10.1097/00007890-199708150-00021 (1997).
Zhu, A. & Hurst, R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9, 376–381 https://doi.org/10.1034/j.1399-3089.2002.02138.x (2002).
Byrne, G., Ahmad-Villiers, S., Du, Z. & McGregor, C. B4GALNT2 and xenotransplantation: a newly appreciated xenogeneic antigen. Xenotransplantation 25, e12394 https://doi.org/10.1111/xen.12394 (2018).
Byrne, G. W., Stalboerger, P. G., Du, Z., Davis, T. R. & McGregor, C. G. Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation 91, 287–292 https://doi.org/10.1097/TP.0b013e318203c27d (2011).
Dehoux, J. P. et al. Specific depletion of preformed IgM natural antibodies by administration of anti-mu monoclonal antibody suppresses hyperacute rejection of pig to baboon renal xenografts. Transplantation 70, 935–946 https://doi.org/10.1097/00007890-200009270-00011 (2000).
Vadori, M. & Cozzi, E. The immunological barriers to xenotransplantation. Tissue Antigens 86, 239–253 https://doi.org/10.1111/tan.12669 (2015).
Cooper, D. K. C., Ekser, B. & Tector, A. J. Immunobiological barriers to xenotransplantation. Int. J. Surg. 23, 211–216 https://doi.org/10.1016/j.ijsu.2015.06.068 (2015).
Muthana, S. M., Xia, L., Campbell, C. T., Zhang, Y. & Gildersleeve, J. C. Competition between serum IgG, IgM, and IgA anti-glycan antibodies. PLoS ONE 10, e0119298 https://doi.org/10.1371/journal.pone.0119298 (2015).
Mattoo, A. et al. The histologic identification of IgA deposits in three cases of porcine to human xenokidney transplantation. Xenotransplantation 32, abstr. 312.4 https://doi.org/10.1111/xen.70067 (2025).
Xu, X.-C., Goodman, J., Sasaki, H., Lowell, J. & Mohanakumar, T. Activation of natural killer cells and macrophages by porcine endothelial cells augments specific T-cell xenoresponse. Am. J. Transplant. 2, 314–322 https://doi.org/10.1034/j.1600-6143.2002.20405.x (2002).
Maeda, A. et al. The innate cellular immune response in xenotransplantation. Front. Immunol. 13, 858604 https://doi.org/10.3389/fimmu.2022.858604 (2022).
Puga Yung, G., Schneider, M. K. J. & Seebach, J. D. The role of NK cells in pig-to-human xenotransplantation. J. Immunol. Res. 2017, 4627384 https://doi.org/10.1155/2017/4627384 (2017).
Forte, P., Lilienfeld, B. G., Baumann, B. C. & Seebach, J. D. Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J. Immunol. 175, 5463–5470 https://doi.org/10.4049/jimmunol.175.8.5463 (2005).
Dai, H. et al. Donor SIRPα polymorphism modulates the innate immune response to allogeneic grafts. Sci. Immunol. 2, eaam6202 https://doi.org/10.1126/sciimmunol.aam6202 (2017).
Navarro-Alvarez, N. & Yang, Y.-G. Lack of CD47 on donor hepatocytes promotes innate immune cell activation and graft loss: a potential barrier to hepatocyte xenotransplantation. Cell Transplant. 23, 345–354 https://doi.org/10.3727/096368913X663604 (2014).
Ide, K. et al. Role for CD47–SIRPα signaling in xenograft rejection by macrophages. Proc. Natl Acad. Sci. USA 104, 5062–5066 https://doi.org/10.1073/pnas.0609661104 (2007).
Hering, B. J. et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat. Med. 12, 301–303 https://doi.org/10.1038/nm1369 (2006).
Goutaudier, V. et al. Spatial multimodal characterization of long-term immune response after pig-to-human kidney xenotransplantation. Am. J. Transplant. 25, S32 https://doi.org/10.1016/j.ajt.2025.07.056 (2025).
Habibabady, Z. et al. Antibody-mediated rejection in xenotransplantation: Can it be prevented or reversed? Xenotransplantation 30, e12816 https://doi.org/10.1111/xen.12816 (2023).
Sykes, M. & Sachs, D. H. Transplanting organs from pigs to humans. Sci. Immunol. 4, eaau6298 https://doi.org/10.1126/sciimmunol.aau6298 (2019).
Singh, A. K. et al. Genetically engineered pig heart transplantation in non-human primates. Commun. Med. 5, 6 https://doi.org/10.1038/s43856-025-00731-y (2025).
Manook, M. et al. Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig. Sci. Transl. Med. 16, eadk6152 https://doi.org/10.1126/scitranslmed.adk6152 (2024).
Diamond, L. E. et al. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation 71, 132–142 https://doi.org/10.1097/00007890-200101150-00021 (2001).
Loveland, B. E. et al. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons. Xenotransplantation 11, 171–183 https://doi.org/10.1046/j.1399-3089.2003.00103.x (2004).
Mohiuddin, M. M. et al. Progressive genetic modifications of porcine cardiac xenografts extend survival to 9 months. Xenotransplantation 29, e12744 https://doi.org/10.1111/xen.12744 (2022).
Azimzadeh, A. M. et al. Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement pathway-regulatory protein. Xenotransplantation 22, 310–316 https://doi.org/10.1111/xen.12176 (2015).
Kroshus, T. J. et al. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 61, 1513–1521 https://doi.org/10.1097/00007890-199605270-00018 (1996).
McCurry, K. R. et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat. Med. 1, 423–427 https://doi.org/10.1038/nm0595-423 (1995).
Petersen, B. et al. Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. Xenotransplantation 18, 355–368 https://doi.org/10.1111/j.1399-3089.2011.00674.x (2011).
Oropeza, M. et al. Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli. Xenotransplantation 16, 522–534 https://doi.org/10.1111/j.1399-3089.2009.00556.x (2009).
Forte, P., Baumann, B. C., Weiss, E. H. & Seebach, J. D. HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am. J. Transplant. 5, 2085–2093 https://doi.org/10.1111/j.1600-6143.2005.00987.x (2005).
Singh, A. K. et al. Cardiac xenografts show reduced survival in the absence of transgenic human thrombomodulin expression in donor pigs. Xenotransplantation 26, e12465 https://doi.org/10.1111/xen.12465 (2019).
Connolly, M. R. et al. Humanized von Willebrand factor reduces platelet sequestration in ex vivo and in vivo xenotransplant models. Xenotransplantation 28, e12712 https://doi.org/10.1111/xen.12712 (2021).
Zhang, W. et al. Genetically engineered pig-to-human liver xenotransplantation. J. Hepatol. 84, 587–598 https://doi.org/10.1016/j.jhep.2025.08.044 (2026).
Lee, K. F. E. et al. Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 15, 191–197 https://doi.org/10.1111/j.1399-3089.2008.00476.x (2008).
Karadagi, A. et al. Multiple human transgenes prolong survival of triple-carbohydrate knockout porcine kidney xenografts in nonhuman primates. Nat. Commun. 17, 8033 https://doi.org/10.1038/s41467-026-74933-w (2026).
Montgomery, R. A., Griesemer, A. D., Segev, D. L. & Sommer, P. The decedent model: a new paradigm for de-risking high stakes clinical trials like xenotransplantation. Am. J. Transplant. 24, 526–532 https://doi.org/10.1016/j.ajt.2024.01.035 (2024).
Cooper, D. K. C. & Kobayashi, T. Xenotransplantation experiments in brain-dead human subjects—a critical appraisal. Am. J. Transplant. 24, 520–525 https://doi.org/10.1016/j.ajt.2023.12.020 (2024).
Meier, R. P. H. et al. International Xenotransplantation Association (IXA) position paper on kidney xenotransplantation. Transplantation 109, 1313–1328 https://doi.org/10.1097/TP.0000000000005372 (2025).
Zhao, Y. et al. Skin graft tolerance across a discordant xenogeneic barrier. Nat. Med. 2, 1211–1216 https://doi.org/10.1038/nm1196-1211 (1996).
Kalscheuer, H. et al. Xenograft tolerance and immune function of human T cells developing in pig thymus xenografts. J. Immunol. 192, 3442–3450 https://doi.org/10.4049/jimmunol.1302886 (2014).
Griesemer, A. D. et al. Results of Gal-knockout porcine thymokidney xenografts. Am. J. Transplant. 9, 2669–2678 https://doi.org/10.1111/j.1600-6143.2009.02849.x (2009).
Locke, J. E., Kumar, V., Anderson, D. & Porrett, P. M. Normal graft function after pig-to-human kidney xenotransplant. JAMA Surg. 158, 1106–1108 https://doi.org/10.1001/jamasurg.2023.2774 (2023).
Cheung, M. D. et al. Spatiotemporal immune atlas of a clinical-grade gene-edited pig-to-human kidney xenotransplant. Nat. Commun. 15, 3140 https://doi.org/10.1038/s41467-024-47454-7 (2024).
Schmauch, E. et al. Multi-omics analysis of a pig-to-human decedent kidney xenotransplant. Nature 650, 205–217 https://doi.org/10.1038/s41586-025-09846-7 (2026). This study presents a longitudinal multi-omics characterization of a 61-day pig-to-human kidney xenotransplant, integrating spatial transcriptomics, scRNA-seq, bulk transcriptomics and T cell receptor sequencing, identifying clonal T cell expansion and pre-existing xenoreactive immunity as drivers of AMR.
Lee, S. A. et al. Physiologic homeostasis in a living human after pig kidney xenotransplantation. Nat. Commun. 16, 8453 https://doi.org/10.1038/s41467-025-63153-3 (2025).
Riella, L. V. et al. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study. Lancet 408, 1029–1040 https://doi.org/10.1016/S0140-6736(26)01295-X (2026). This study reports a pig kidney xenograft that kept a living recipient dialysis-free for 271 days, with serial biopsies, multiplex immunofluorescence, targeted transcriptomics and porcine cfDNA tracing early T cell-mediated rejection through to late microvascular injury and thrombotic microangiopathy.
Loupy, A., Sannier, A. & Oniscu, G. C. Kidney xenotransplantation—bridge to allotransplantation or destination treatment? Lancet 408, 976–978 https://doi.org/10.1016/s0140-6736(26)01479-0 (2026).
Guo, Q. et al. Longitudinal multi-omics profiling reveals molecular responses in a living human receiving a gene-edited pig kidney xenograft. Am. J. Transplant. 25, S30 https://doi.org/10.1016/j.ajt.2025.07.051 (2025).
Montgomery, R. et al. Longest surviving recipient of a xenotransplant: allo-sensitized patient receiving a 10 gene-edited pig kidney. Am. J. Transplant. 25, S25 https://doi.org/10.1016/j.ajt.2025.07.040 (2025).
Cooper, D. K. C., Yamamoto, T., Hara, H. & Pierson, R. N. III. The first clinical pig heart transplant: was IVIg or pig cytomegalovirus detrimental to the outcome? Xenotransplantation 29, e12771 https://doi.org/10.1111/xen.12771 (2022).
Schmauch, E. et al. Integrative multi-omics profiling in human decedents receiving pig heart xenografts. Nat. Med. 30, 1448–1460 https://doi.org/10.1038/s41591-024-02972-1 (2024). This study reports multi-omics characterization of pig-to-human cardiac xenografts in human decedents, combining transcriptomics, proteomics, metabolomics and single-cell profiling, identifying perioperative cardiac xenograft dysfunction and metabolic crisis as key injury patterns that are not apparent on conventional assessment.
Giarraputo, A. et al. Characterizing the immune response in pig-to-human heart xenografts using a multimodal diagnostic system. Circulation 152, 1552–1563 https://doi.org/10.1161/circulationaha.125.074971 (2025).
Shirini, K. & Meier, R. P. H. Systematic review and comparative outcomes analysis of NHP liver allotransplants and xenotransplants. Xenotransplantation 32, e70017 https://doi.org/10.1111/xen.70017 (2025).
Czigany, Z. et al. A snapshot of challenges and opportunities faced by the scientific workforce in liver transplantation-a survey of the International Liver Transplantation Society (ILTS). Liver Transpl. 31, 1007–1019 https://doi.org/10.1097/LVT.0000000000000599 (2025).
Chari, R. S. et al. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N. Engl. J. Med. 331, 234–237 https://doi.org/10.1056/NEJM199407283310404 (1994).
Horslen, S. P. et al. Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 70, 1472–1478 https://doi.org/10.1097/00007890-200011270-00014 (2000).
Pullen, L. C. Extracorporeal liver support with a porcine liver: the United States Food and Drug Administration approves the first trial. Am. J. Transplant. 25, 1589–1591 https://doi.org/10.1016/j.ajt.2025.06.022 (2025).
Zhao, L. et al. Graft-derived VWF drives platelet activation and thrombocytopenia during porcine liver xenotransplantation to brain-dead human recipients. J. Clin. Invest. 136, e200800 https://doi.org/10.1172/JCI200800 (2026).
Cross-Najafi, A. A. et al. Current barriers to clinical liver xenotransplantation. Front. Immunol. 13, 827535 https://doi.org/10.3389/fimmu.2022.827535 (2022).
Zhang, X. et al. A review of pig liver xenotransplantation: Current problems and recent progress. Xenotransplantation 26, e12497 https://doi.org/10.1111/xen.12497 (2019).
Ekser, B., Markmann, J. F. & Tector, A. J. Current status of pig liver xenotransplantation. Int. J. Surg. 23, 240–246 https://doi.org/10.1016/j.ijsu.2015.06.083 (2015).
Ekser, B. & Fernandez, L. A. Promise and pitfalls of liver xenotransplantation. Nat. Rev. Gastroenterol. Hepatol. 22, 527–528 https://doi.org/10.1038/s41575-025-01093-5 (2025).
Tao, K. et al. Orthotopic liver xenotransplantation from gene-modified pig to decedent human. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-026-01797-2 (2026).
He, S. et al. Incidence of serum antibodies to xenoantigens on triple-knockout pig cells in different human groups. Xenotransplantation 31, e12818 https://doi.org/10.1111/xen.12818 (2024).
Higginbotham, L. et al. Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model. Xenotransplantation 22, 221–230 https://doi.org/10.1111/xen.12166 (2015).
Avery, R. K. et al. Optimizing IVIg in xenotransplantation: a call to action. Transplantation 110, 1157 https://doi.org/10.1097/TP.0000000000005402 (2025).
Park, S. et al. European Society of Organ Transplantation consensus statement on testing for non-invasive diagnosis of kidney allograft rejection. Transpl. Int. 36, 12115 https://doi.org/10.3389/ti.2023.12115 (2023).
Merola, J., Emond, J. C. & Levitsky, J. Novel noninvasive biomarkers in liver transplantation: a tool on the doorstep of clinical utilization. Transplantation 107, 2120–2125 https://doi.org/10.1097/TP.0000000000004580 (2023).
Parajuli, S. et al. The trend of serum creatinine does not predict follow-up biopsy findings among kidney transplant recipients with antibody-mediated rejection. Transplant. Direct. 9, e1489 https://doi.org/10.1097/TXD.0000000000001489 (2023).
Aubert, O. et al. Cell-free DNA for the detection of kidney allograft rejection. Nat. Med. 30, 2320–2327 https://doi.org/10.1038/s41591-024-03087-3 (2024).
Fishman, J. A. et al. Infectious disease surveillance and management in clinical xenotransplantation: experience with the first human porcine kidney transplant. Am. J. Transplant. 25, 2451–2457 https://doi.org/10.1016/j.ajt.2025.06.016 (2025).
Agbor-Enoh, S. et al. Circulating cell-free DNA as a biomarker of tissue injury: Assessment in a cardiac xenotransplantation model. J. Heart Lung Transplant. 37, 967–975 https://doi.org/10.1016/j.healun.2018.04.009 (2018).
Adams, A. B. et al. Anti-C5 antibody tesidolumab reduces early antibody-mediated rejection and prolongs survival in renal xenotransplantation. Ann. Surg. 274, 473–480 https://doi.org/10.1097/Sla.0000000000004996 (2021).
Ma, D. et al. Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques. Am. J. Transplant. 22, 46–57 https://doi.org/10.1111/ajt.16780 (2022).
Anwar, I. J. et al. CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. Sci. Transl. Med. 17, eadn8130 https://doi.org/10.1126/scitranslmed.adn8130 (2025).
Mohiuddin, M. M. et al. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. Nat. Commun. 7, 11138 https://doi.org/10.1038/ncomms11138 (2016).
Kawai, T., Andrews, D., Colvin, R. B., Sachs, D. H. & Cosimi, A. B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6, 114 https://doi.org/10.1038/72162 (2000).
Kim, S. C. et al. Fc-silent anti-CD154 domain antibody effectively prevents nonhuman primate renal allograft rejection. Am. J. Transplant. 17, 1182–1192 https://doi.org/10.1111/ajt.14197 (2017).
Miura, S. et al. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. Am. J. Transplant. 23, 1182–1193 https://doi.org/10.1016/j.ajt.2023.03.025 (2023).
Alexander, K. L., Bennion, K. B., Liu, D. & Ford, M. L. CD154:CD11b blockade enhances CD8+ T cell differentiation during infection but not transplantation. JCI Insight 10, e184843 https://doi.org/10.1172/jci.insight.184843 (2025).
Thompson, P. et al. Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am. J. Transplant. 12, 1765–1775 https://doi.org/10.1111/j.1600-6143.2012.04031.x (2012).
Eisenson, D. et al. Consistent survival in consecutive cases of life-supporting porcine kidney xenotransplantation using 10GE source pigs. Nat. Commun. 15, 3361 https://doi.org/10.1038/s41467-024-47679-6 (2024).
Mohiuddin, M. M. et al. Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model. Xenotransplantation 21, 35–45 https://doi.org/10.1111/xen.12066 (2014).
Firl, D. J. et al. Clinical and molecular correlation defines activity of physiological pathways in life-sustaining kidney xenotransplantation. Nat. Commun. 14, 3022 https://doi.org/10.1038/s41467-023-38465-x (2023).
Kim, S. C. et al. Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion. Am. J. Transplant. 19, 2174–2185 https://doi.org/10.1111/ajt.15329 (2019).
Shah, J. A. et al. Remaining physiological barriers in porcine kidney xenotransplantation: potential pathways behind proteinuria as well as factors related to growth discrepancies following pig-to-kidney xenotransplantation. J. Immunol. Res. 2018, 6413012 https://doi.org/10.1155/2018/6413012 (2018).
Iwase, H. et al. Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date. Xenotransplantation 22, 302–309 https://doi.org/10.1111/xen.12174 (2015).
Iwase, H. et al. Pig-to-baboon heterotopic heart transplantation–exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation 22, 211–220 https://doi.org/10.1111/xen.12167 (2015).
Lu, T., Yang, B., Wang, R. & Qin, C. Xenotransplantation: current status in preclinical research. Front. Immunol. 10, 3060 https://doi.org/10.3389/fimmu.2019.03060 (2020).
Mitchell, C. B. et al. Early results of an infant model of orthotopic cardiac xenotransplantation. J. Heart Lung Transplant. 44, 503–510 https://doi.org/10.1016/j.healun.2024.12.011 (2025).
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. & Tang, Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 18, 749–769 https://doi.org/10.1038/s41573-019-0041-4 (2019).
Porret, R. et al. Regulatory T cell therapy for xenotransplantation, what perspectives? Front. Immunol. 16, 1685682 https://doi.org/10.3389/fimmu.2025.1685682 (2025).
Singh, A. K. et al. CD4+CD25hiFoxP3+ regulatory T cells in long-term cardiac xenotransplantation. Xenotransplantation 25, e12379 https://doi.org/10.1111/xen.12379 (2018).
Meier, R. P. H. et al. Xenotransplantation: back to the future? Transpl. Int. 31, 465–477 https://doi.org/10.1111/tri.13104 (2018).
Lamers, C. et al. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. Nat. Commun. 13, 5519 https://doi.org/10.1038/s41467-022-33003-7 (2022).
Loupy, A., Sablik, M., Khush, K. & Reese, P. P. Advancing patient monitoring, diagnostics, and treatment strategies for transplant precision medicine. Lancet 406, 389–402 https://doi.org/10.1016/S0140-6736(25)00195-3 (2025).
Fishman, J. A., Denner, J. & Scobie, L. International Xenotransplantation Association (IXA) position paper on infectious disease considerations in xenotransplantation. Xenotransplantation 32, e70001 https://doi.org/10.1111/xen.70001 (2025).
Horton, R. Xenotransplantation–a new era beckons. Lancet 404, 1181 https://doi.org/10.1016/S0140-6736(24)02130-5 (2024).
Patel, P. M. et al. Minimizing ischemia reperfusion injury in xenotransplantation. Front. Immunol. 12, 681504 https://doi.org/10.3389/fimmu.2021.681504 (2021).
Loupy, A. et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 366, l4923 https://doi.org/10.1136/bmj.l4923 (2019).
Zielinski, D. et al. Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: a multicenter international study. Am. J. Transplant. 25, 1631–1642 https://doi.org/10.1016/j.ajt.2025.04.025 (2025).
Hu, X., Hawthorne, W. J. & Buhler, L. The International Human Xenotransplantation Inventory: current data and future directions. Transplantation 109, 1329–1334 https://doi.org/10.1097/TP.0000000000005367 (2025).
Loupy, A., Mengel, M. & Haas, M. Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics. Kidney Int. 101, 678–691 https://doi.org/10.1016/j.kint.2021.11.028 (2022).
Rosales, I. A. et al. Pathologic evaluation of pig kidney and heart xenografts: 2024 recommendations from the Banff Xenotransplantation Pathology Working Group. Am. J. Transplant. 26, 1561–1576 https://doi.org/10.1016/j.ajt.2026.04.011 (2026).
Hisadome, Y. et al. Hypothermic machine perfusion prevents hyperacute graft loss in pig-to-primate kidney xenotransplantation after 5-hours of cold Ischemia. Commun. Med. 5, 117 https://doi.org/10.1038/s43856-025-00842-6 (2025).
Rivest, F. et al. Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics. Sci. Rep. 13, 16994 https://doi.org/10.1038/s41598-023-43435-w (2023).
Sheng, W. et al. Multiplex immunofluorescence: a powerful tool in cancer immunotherapy. Int. J. Mol. Sci. 23, 3086 https://doi.org/10.3390/ijms24043086 (2023).
Giarraputo, A. et al. Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling. Eur. Heart J. 47, 956–970 https://doi.org/10.1093/eurheartj/ehaf949 (2025).
Mengel, M. et al. Banff 2019 Meeting Report: molecular diagnostics in solid organ transplantation–consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am. J. Transplant. 20, 2305–2317 https://doi.org/10.1111/ajt.16059 (2020).
White, B. S. et al. Community assessment of methods to deconvolve cellular composition from bulk gene expression. Nat. Commun. 15, 7362 https://doi.org/10.1038/s41467-024-50618-0 (2024).
Zhao, K. & Rhee, S. Y. Interpreting omics data with pathway enrichment analysis. Trends Genet. 39, 308–319 https://doi.org/10.1016/j.tig.2023.01.003 (2023).
Marx, V. Method of the Year: spatially resolved transcriptomics. Nat. Methods 18, 9–14 https://doi.org/10.1038/s41592-020-01033-y (2021).
Gaspard-Boulinc, L. C., Gortana, L., Walter, T., Barillot, E. & Cavalli, F. M. G. Cell-type deconvolution methods for spatial transcriptomics. Nat. Rev. Genet. 26, 828–846 https://doi.org/10.1038/s41576-025-00845-y (2025).
Tasca, P. et al. Application of spatial-omics to the classification of kidney biopsy samples in transplantation. Nat. Rev. Nephrol. 20, 755–766 https://doi.org/10.1038/s41581-024-00861-x (2024).
Zheng, Y. et al. Multi-omics data integration using ratio-based quantitative profiling with Quartet reference materials. Nat. Biotechnol. 42, 1133–1149 https://doi.org/10.1038/s41587-023-01934-1 (2024).
Athieniti, E. & Spyrou, G. M. A guide to multi-omics data collection and integration for translational medicine. Comput. Struct. Biotechnol. J. 21, 134–149 https://doi.org/10.1016/j.csbj.2022.11.050 (2023).
Novikova, E. et al. Coordinated circulating and tissue-based T cell responses precede xenograft rejection. Preprint at bioRxiv https://doi.org/10.1101/2025.11.07.687259 (2025).
Ladowski, J. M. & Meier, R. P. H. Xenotransplantation in living human recipients: where we stand in 2026: vital insights into xenotransplantation. Am. J. Transplant. 26, 913–915 https://doi.org/10.1016/j.ajt.2026.02.039 (2026).
Nature · সাধারণ
Multimodal precision diagnostics in clinical xenotransplantation
২২/১০/২০২৬
